Bill · HR
H.R. 946 (119th)
ORPHAN Cures Act
Original
Introduced
4 February 2025
Last action
6 February 2025 · Introduced
Status
Sponsor introductory remarks on measure. (CR H535-536)
Sponsors
John Joyce, Donald Davis, Rep. Hern, Kevin [R-OK-1], Scott Peters, Mariannette Miller-Meeks, William Keating, Rep. Hudson, Richard [R-NC-9], Shri Thanedar, Rep. Bilirakis, Gus M. [R-FL-12], Rep. Gottheimer, Josh [D-NJ-5], Lloyd Smucker, Janelle Bynum, Thomas Kean, Dina Titus, Andrea Salinas, Rep. Dunn, Neal P. [R-FL-2], Adam Gray, Rep. Crenshaw, Dan [R-TX-2], Robert Bresnahan
Subjects
Healthcare
Source updated
5 December 2025
Summary
Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition. The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
4 February 2025
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
4 February 2025
Introduced
Introduced in House
Source: IntroReferral
4 February 2025
Introduced
Introduced in House
Source: IntroReferral
6 February 2025
Introduced
Sponsor introductory remarks on measure. (CR H535-536)
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in House
Introduced in House · EN · 4 February 2025
Introduced in House
summary · EN · 4 February 2025
Sponsors
- John Joyce · R · Sponsor
- Donald Davis · D · Sponsor
- Rep. Hern, Kevin [R-OK-1] · R · Sponsor
- Scott Peters · D · Sponsor
- Mariannette Miller-Meeks · R · Sponsor
- William Keating · D · Sponsor
- Rep. Hudson, Richard [R-NC-9] · R · Sponsor
- Shri Thanedar · D · Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12] · R · Sponsor
- Rep. Gottheimer, Josh [D-NJ-5] · D · Sponsor
- Lloyd Smucker · R · Cosponsor
- Janelle Bynum · D · Cosponsor
- Thomas Kean · R · Cosponsor
- Dina Titus · D · Cosponsor
- Andrea Salinas · D · Cosponsor
- Rep. Dunn, Neal P. [R-FL-2] · R · Cosponsor
- Adam Gray · D · Cosponsor
- Rep. Crenshaw, Dan [R-TX-2] · R · Cosponsor
- Robert Bresnahan · R · Cosponsor
- · hswm00 · Standing
- · hsif00 · Standing
Related records
- related to ← ORPHAN Cures Act
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/119th-congress/house-bill/946
- Open data entity: https://api.congress.gov/v3/bill/119/hr/946
- us · 119-hr-946 · source updated 5 December 2025